Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: ERGIC1

Gene summary for ERGIC1

Gene summary.

Gene information	Species	Human
	Gene symbol	ERGIC1
	Gene ID	57222
	Gene name	endoplasmic reticulum-golgi intermediate compartment 1
	Gene Alias	AMC2
	Cytomap	5q35.1
	Gene Type	protein-coding
	GO ID	GO:0006810
	UniProtAcc	Q969X5

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
57222	ERGIC1	GSM4909290	Human	Breast	IDC	4.57e-02	2.02e-01	0.2096
57222	ERGIC1	GSM4909291	Human	Breast	IDC	1.12e-07	3.74e-01	0.1753
57222	ERGIC1	GSM4909292	Human	Breast	IDC	6.36e-05	6.16e-01	0.1236
57222	ERGIC1	GSM4909293	Human	Breast	IDC	4.06e-37	6.27e-01	0.1581
57222	ERGIC1	GSM4909297	Human	Breast	IDC	7.59e-03	4.13e-02	0.1517
57222	ERGIC1	GSM4909298	Human	Breast	IDC	1.06e-32	6.43e-01	0.1551
57222	ERGIC1	GSM4909304	Human	Breast	IDC	4.29e-07	2.72e-01	0.1636
57222	ERGIC1	GSM4909308	Human	Breast	IDC	4.45e-11	3.52e-01	0.158
57222	ERGIC1	GSM4909311	Human	Breast	IDC	1.13e-10	2.18e-02	0.1534
57222	ERGIC1	GSM4909312	Human	Breast	IDC	5.41e-05	2.13e-01	0.1552
57222	ERGIC1	GSM4909317	Human	Breast	IDC	4.67e-08	3.30e-01	0.1355
57222	ERGIC1	GSM4909319	Human	Breast	IDC	3.26e-15	-2.93e-02	0.1563
57222	ERGIC1	GSM4909321	Human	Breast	IDC	4.99e-05	1.84e-01	0.1559
57222	ERGIC1	M1	Human	Breast	IDC	7.65e-11	4.43e-01	0.1577
57222	ERGIC1	NCCBC14	Human	Breast	DCIS	4.88e-03	1.18e-01	0.2021
57222	ERGIC1	P1	Human	Breast	IDC	1.09e-03	1.47e-01	0.1527
57222	ERGIC1	DCIS2	Human	Breast	DCIS	7.46e-39	1.22e-01	0.0085
57222	ERGIC1	HTA11_2487_2000001011	Human	Colorectum	SER	8.65e-14	7.93e-01	-0.1808
57222	ERGIC1	HTA11_1938_2000001011	Human	Colorectum	AD	7.57e-12	6.99e-01	-0.0811
57222	ERGIC1	HTA11_78_2000001011	Human	Colorectum	AD	2.51e-21	1.07e+00	-0.1088

Page: 1 2 3 4 5 6 7 8 9 10

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Breast		IDC: Invasive ductal carcinoma
		DCIS: Ductal carcinoma in situ
		Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers
Colorectum (GSE201348)		FAP: Familial adenomatous polyposis
		CRC: Colorectal cancer
Colorectum (HTA11)		AD: Adenomas
		SER: Sessile serrated lesions
		MSI-H: Microsatellite-high colorectal cancer
		MSS: Microsatellite stable colorectal cancer
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Prostate		BPH: Benign Prostatic Hyperplasia
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:000689017	Esophagus	ESCC	retrograde vesicle-mediated transport, Golgi to endoplasmic reticulum	46/8552	52/18723	1.23e-10	3.66e-09	46
GO:00481936	Liver	NAFLD	Golgi vesicle transport	66/1882	296/18723	3.66e-10	9.30e-08	66
GO:00068885	Liver	NAFLD	endoplasmic reticulum to Golgi vesicle-mediated transport	26/1882	130/18723	4.78e-04	6.78e-03	26
GO:004819311	Liver	Cirrhotic	Golgi vesicle transport	153/4634	296/18723	1.02e-23	6.43e-21	153
GO:000688811	Liver	Cirrhotic	endoplasmic reticulum to Golgi vesicle-mediated transport	77/4634	130/18723	5.78e-17	7.56e-15	77
GO:00068905	Liver	Cirrhotic	retrograde vesicle-mediated transport, Golgi to endoplasmic reticulum	29/4634	52/18723	1.69e-06	3.22e-05	29
GO:004819321	Liver	HCC	Golgi vesicle transport	217/7958	296/18723	2.58e-27	1.02e-24	217
GO:000688821	Liver	HCC	endoplasmic reticulum to Golgi vesicle-mediated transport	100/7958	130/18723	1.15e-15	8.67e-14	100
GO:000689011	Liver	HCC	retrograde vesicle-mediated transport, Golgi to endoplasmic reticulum	36/7958	52/18723	8.79e-05	7.66e-04	36
GO:004819315	Oral cavity	OSCC	Golgi vesicle transport	209/7305	296/18723	1.39e-28	6.30e-26	209
GO:00068888	Oral cavity	OSCC	endoplasmic reticulum to Golgi vesicle-mediated transport	97/7305	130/18723	1.42e-16	1.15e-14	97
GO:000689010	Oral cavity	OSCC	retrograde vesicle-mediated transport, Golgi to endoplasmic reticulum	40/7305	52/18723	2.86e-08	5.50e-07	40
GO:004819316	Oral cavity	LP	Golgi vesicle transport	141/4623	296/18723	6.11e-18	1.06e-15	141
GO:000688814	Oral cavity	LP	endoplasmic reticulum to Golgi vesicle-mediated transport	67/4623	130/18723	3.74e-11	2.39e-09	67
GO:000689015	Oral cavity	LP	retrograde vesicle-mediated transport, Golgi to endoplasmic reticulum	29/4623	52/18723	1.60e-06	3.79e-05	29
GO:004819310	Prostate	BPH	Golgi vesicle transport	102/3107	296/18723	3.90e-14	4.56e-12	102
GO:00068887	Prostate	BPH	endoplasmic reticulum to Golgi vesicle-mediated transport	46/3107	130/18723	1.53e-07	3.53e-06	46
GO:00068909	Prostate	BPH	retrograde vesicle-mediated transport, Golgi to endoplasmic reticulum	21/3107	52/18723	3.85e-05	4.18e-04	21
GO:004819314	Prostate	Tumor	Golgi vesicle transport	105/3246	296/18723	3.55e-14	4.33e-12	105
GO:000688813	Prostate	Tumor	endoplasmic reticulum to Golgi vesicle-mediated transport	49/3246	130/18723	2.49e-08	8.33e-07	49

Page: 1 2 3

Enriched KEGG pathways.

Pathway ID

Tissue

Disease Stage

Description

Gene Ratio

Bg Ratio

pvalue

p.adjust

qvalue

Count

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

ERGIC1

SNV

Missense_Mutation

novel

c.854A>T

p.Gln285Leu

p.Q285L

Q969X5

protein_coding

deleterious(0.03)

benign(0.138)

TCGA-BH-A0B1-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Chemotherapy

adriamycin

ERGIC1

SNV

Missense_Mutation

novel

c.605N>T

p.Lys202Met

p.K202M

Q969X5

protein_coding

deleterious(0.03)

possibly_damaging(0.575)

TCGA-BH-A0EE-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Chemotherapy

docetaxel

ERGIC1

insertion

Frame_Shift_Ins

novel

c.649_650insAGGGAGGGAGGGGC

p.Val217GlufsTer125

p.V217Efs*125

Q969X5

protein_coding

TCGA-A2-A0EU-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

ERGIC1

insertion

Frame_Shift_Ins

novel

c.855_856insGGGCTGCTAATGTCCTCTGGGGCCACACAACTGTTTATTTCTT

p.Leu286GlyfsTer26

p.L286Gfs*26

Q969X5

protein_coding

TCGA-BH-A0B1-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Chemotherapy

adriamycin

ERGIC1

insertion

Frame_Shift_Ins

novel

c.604_605insCT

p.Lys202ThrfsTer136

p.K202Tfs*136

Q969X5

protein_coding

TCGA-BH-A0EE-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Chemotherapy

docetaxel

ERGIC1

insertion

Frame_Shift_Ins

novel

c.839_840insTCTGTCCTTTGTAGCACTTGCCTTGG

p.Trp281LeufsTer65

p.W281Lfs*65

Q969X5

protein_coding

TCGA-BH-A0HB-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

docetaxel

ERGIC1

SNV

Missense_Mutation

c.577N>T

p.Pro193Ser

p.P193S

Q969X5

protein_coding

deleterious(0.01)

probably_damaging(1)

TCGA-FU-A3HZ-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

ERGIC1

SNV

Missense_Mutation

novel

c.320N>C

p.Ile107Thr

p.I107T

Q969X5

protein_coding

tolerated(0.42)

benign(0.005)

TCGA-EI-6507-01

Colorectum

rectum adenocarcinoma

Male

<65

I/II

Unknown

ERGIC1

SNV

Missense_Mutation

novel

c.433N>T

p.Asp145Tyr

p.D145Y

Q969X5

protein_coding

deleterious(0)

probably_damaging(0.995)

TCGA-A5-A0G2-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

III/IV

Unknown

ERGIC1

SNV

Missense_Mutation

rs376307473

c.695N>A

p.Arg232His

p.R232H

Q969X5

protein_coding

deleterious(0.05)

probably_damaging(0.988)

TCGA-AJ-A3NE-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

I/II

Unknown

Page: 1 2 3 4

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1